The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinics in oncology

• Publication date

  2004-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.CLON.2004.06.007PMID 15630849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transposon Silencing Keeps Jumping Genes in Their Place

  2006cited by this paper
• Primærbehandling av ovarialcancer

  2005cited by this paper
• Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.

  2005cited by this paper
• Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data

  2003cited by this paper
• Placebo effects in oncology.

  2003cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

  2003cited by this paper
• Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?

  2003cited by this paper
• Stem-cell transplantation for high-risk breast cancer.

  2003cited by this paper
• Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival.

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.

  2003cited by this paper
• Is relative risk reduction a useful measure for patients or families who must choose a method of treatment?

  2003cited by this paper
• Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.

  2003cited by this paper
• Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

  2003cited by this paper
• Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

  2002cited by this paper
• Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.

  2002cited by this paper
• Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

  2002cited by this paper
• Efficacy, safety, and cost of new anticancer drugs

  2002cited by this paper
• Is the NICE process flawed?

  2002cited by this paper
• Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

  2002influential reference
• Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction

  2002cited by this paper
• Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.

  2001cited by this paper
• Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment.

  2001cited by this paper
• A "bureausceptic" view of cancer drug rationing.

  2001cited by this paper
• Measuring the clinical response. What does it mean?

  2001cited by this paper
• Is the placebo powerless?

  2001cited by this paper
• Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

  2001cited by this paper
• Non-curative chemotherapy for cancer--is it worth it?

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

  2001cited by this paper
• Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP

  2001cited by this paper
• Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix.

  2001cited by this paper
• A randomized Phase II trial in patients with carcinoma of an unknown primary site

  2001cited by this paper
• Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?

  2001cited by this paper
• Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis.

  2001cited by this paper
• Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

  2000cited by this paper
• A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.

  2000cited by this paper
• Neoadjuvant cisplatin for advanced bladder cancer.

  2000cited by this paper
• The logic of evidence.

  2000cited by this paper
• Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

  2000cited by this paper
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial.

  2000cited by this paper
• Non-small-cell lung cancer--stalemate or progress?

  2000cited by this paper
• Achievements and future of chemotherapy.

  2000cited by this paper
• Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.

  2000cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data

  2000cited by this paper
• Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials.

  1999cited by this paper
• Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

  1999cited by this paper
• The tea leaves of small trials.

  1999cited by this paper
• Detection of anthracycline-induced cardiotoxicity.

  1999cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators.

  1999cited by this paper
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

  1999cited by this paper
• Surgical management of breast cancer in Australia in 1995

  1999cited by this paper
• Missing quality of life data in cancer clinical trials: serious problems and challenges.

  1998cited by this paper
• Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

  1998cited by this paper
• Do patients with advanced breast cancer benefit from chemotherapy?

  1998cited by this paper
• Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

  1998cited by this paper
• Conventional cancer therapy: promise broken or promise delayed?

  1998cited by this paper
• Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

  1998cited by this paper
• Inadequate documentation and resection for gastric cancer in the United States: a preliminary report.

  1998cited by this paper
• Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis.

  1998cited by this paper
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.

  1998cited by this paper
• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

  1998cited by this paper
• Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.

  1997cited by this paper
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.

  1997cited by this paper
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.

  1997cited by this paper
• Adjuvant chemotherapy in colorectal carcinoma

  1997cited by this paper
• Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide.

  1997cited by this paper
• Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

  1997cited by this paper
• Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer.

  1997cited by this paper
• Surgical management of breast cancer in Australian women in 1993: analysis of Medicare statistics

  1997cited by this paper
• Management of seminoma of the testis: recommendations based on treatment results.

  1997cited by this paper
• Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer

  1996cited by this paper
• Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.

  1996cited by this paper
• Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin

  1996cited by this paper
• 3 The Cochrane Library

  1996cited by this paper
• Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

  1996cited by this paper
• An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.

  1995cited by this paper
• Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials.

  1995cited by this paper
• Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration.

  1995cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.

  1995cited by this paper
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper
• Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.

  1995cited by this paper
• Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

  1993cited by this paper
• A cry from the fringe.

  1993cited by this paper
• Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

  1993cited by this paper
• Cancer of the stomach. A patient care study by the American College of Surgeons.

  1993cited by this paper
• Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.

  1993cited by this paper
• Long-term survival with advanced ovarian cancer: an analysis of 5-year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy.

  1992cited by this paper
• Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

  1992cited by this paper
• Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

  1991cited by this paper
• Medical oncology in the 1990s.

  1991cited by this paper
• Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis

  1991cited by this paper
• Medical oncology in the 1990s.

  1991influential reference

• In Situ Vaccination by Nanomedicine Approach for Cancer Immunotherapy

  2026cites this paper
• Chimeric antigen receptor cells as a tool for localized delivery of TNFα in solid cancer treatment

  2025cites this paper
• Evaluation of 30-day mortality rate following intravenous systemic anticancer therapy: a retrospective analysis

  2025cites this paper
• Volatiles vs. TIVA – Is there a difference in cancer patients

  2025cites this paper
• Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies

  2025influential citation
• The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data

  2025cites this paper
• Cancer, precision medicine, and Atlantic Canada: A priority setting exercise by the Atlantic Cancer Consortium Patient Advisory Committee

  2025cites this paper
• Sustainable Nanomaterials for Precision Medicine in Cancer Therapy

  2024cites this paper
• Evaluation of the Efficiency of the Magicramp^® Device for Reducing Cramps Resulting from Oncological Treatments: “Double-Blind, Randomized Clinical Trial”

  2024cites this paper
• Proteomic analysis of two novel peptides from the Odontobuthus doriae scorpion venom

  2024cites this paper
• Cancer as a global health crisis with deep evolutionary roots

  2024cites this paper
• CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer.

  2023cites this paper
• Targeted Sensitization of Glioblastoma Multiforme Using AAAPT Technology

  2023cites this paper
• An updated landscape on nanotechnology-based drug delivery, immunotherapy, vaccinations, imaging, and biomarker detections for cancers: recent trends and future directions with clinical success

  2023cites this paper
• A 15 Year Evolution of Dichloroacetate-Based Metabolic Cancer Therapy: A Review with Case Reports

  2023cites this paper
• Predictive validity in drug discovery: what it is, why it matters and how to improve it

  2022cites this paper
• When Will the FDA Do What Is in People’s Best Interests?

  2022cites this paper
• The Neurokinin-1 Receptor: A Promising Antitumor Target

  2022cites this paper
• Meta-Analysis Reveals Both the Promises and the Challenges of Clinical Metabolomics

  2022cites this paper
• FDA Should Re-evaluate All mRNA Vaccines and Revoke Their Use Authorizations (The Short Version).

  2022cites this paper
• Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression

  2022cites this paper
• Progress of Folic Acid-Folate Receptor as Drug Carriers in Targeted Drug Delivery System

  2022cites this paper
• OncoRx: An Integrative Approach to Pan-Cancer Biomarker Identification and Targeted Cancer Multi-Drug Regimen Prediction

  2022cites this paper
• Revisiting Epithelial Carcinogenesis

  2022cites this paper
• Introduction: The Costly War on Cancer

  2022cites this paper
• Radical Cancer Treatments Promote Cancer Growth Speeds and Shorten Patient Lives: A Comprehensive Evidence Study

  2022influential citation
• Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation

  2022cites this paper
• Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?

  2022cites this paper
• The Effect of Propofol versus Inhalation Anesthetics on Survival after Oncological Surgery

  2022cites this paper
• Increased glucose availability sensitizes pancreatic cancer to chemotherapy

  2022influential citation
• Surgery, Chemotherapy and Radiotherapy May Promote Cancer Growth Speeds and Shorten Patient Lives

  2022cites this paper
• Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome

  2021cites this paper
• Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC

  2021cites this paper
• Pharmacoepidemiology for oncology clinical practice: Foundations, state of the art and perspectives.

  2021cites this paper
• Personalised Precision Medicine- a Novel Approach for Oral Cancer Management

  2021cites this paper
• DFF40 deficiency in cancerous T cells is implicated in chemotherapy drug sensitivity and resistance through the regulation of the apoptotic pathway.

  2021cites this paper
• Person-to-Person Cancer Transmission via Allogenic Blood Transfusion

  2021influential citation
• Abject Ontologies: Cancer and ‘Living On’

  2021cites this paper
• Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies

  2021cites this paper
• Parametric and semiparametric copula-based models for the regression analysis of competing risks

  2021cites this paper
• On the Origin of Carcinoma

  2021cites this paper
• A macromolecular drug for cancer therapy via extracellular calcification.

  2021cites this paper
• Benchmarking prognosis methods for survivability - A case study for patients with contingent primary cancers

  2021cites this paper
• Metastatic risk stratification of leiomyosarcoma patients using transcription- and replication-associated chromosomal instability mechanisms

  2021cites this paper
• Assessment of Depression and Anxiety in Breast Cancer Patients Undergoing Radiotherapy in Palestine

  2020cites this paper
• Challenges for the Optimization of Drug Therapy in the Treatment of Cancer

  2020cites this paper
• Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation

  2020cites this paper
• The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?

  2020cites this paper
• Survivability modelling using Bayesian network for patients with first and secondary primary cancers

  2020cites this paper
• Mortality and morbidity of curative and palliative anticancer treatments during the COVID-19 pandemic: A multicenter population-based retrospective study

  2020cites this paper
• Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility

  2020cites this paper
• Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

  2020cites this paper
• Actinoporins: From the Structure and Function to the Generation of Biotechnological and Therapeutic Tools

  2020cites this paper
• Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

  2020cites this paper
• The functional role of long noncoding RNA in resistance to anticancer treatment

  2020cites this paper
• Clinical Utility of Molecular Genetic Cancer Profiling

  2020cites this paper
• [The medicine of cancer: can the solutions be found in our own back yard?]

  2019cites this paper
• Identification of Frailty in Geriatric Oncologic Patients

  2019cites this paper
• Erythrocyte leveraged chemotherapy (ELeCt): Nanoparticle assembly on erythrocyte surface to combat lung metastasis

  2019cites this paper
• Surgery, Chemotherapy and Radiotherapy Promote Cancer Growth Speeds and Shorten Patient Lives

  2019cites this paper
• Cognitive impairment after cytotoxic chemotherapy.

  2019cites this paper
• A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed

  2019cites this paper
• Is there any benefit to particles over photon radiotherapy?

  2019cites this paper
• Expanding Metabolic Targets in Cancer by Select Combinations of Vitamin C and EGCG with Different Natural Compounds

  2019cites this paper
• Ultimate dynamics and optimal control of a multi-compartment model of tumor resistance to chemotherapy

  2019cites this paper
• Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy

  2019cites this paper
• Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning.

  2019cites this paper
• Cancer Quackery and Fake News: Targeting the Most Vulnerable

  2019cites this paper
• Neurokinin-1 Receptor Antagonists as Anticancer Drugs

  2019cites this paper
• Clinical evaluation of carcinoembryonic and carbohydrate antigens as cancer biomarkers to monitor palliative chemotherapy in advanced stage gastric cancer.

  2019cites this paper
• Immunity or morphogenesis in cancer development and treatment

  2019cites this paper
• Dynamics of tumor growth: chemotherapy and integrative oncology

  2019cites this paper
• Anticancer activity of Giloe, Tinospora Cordifoila (Willd.) Miers Ex Hook F & Thoms

  2019cites this paper
• The Mismatch of Nutrition and “Medical Practice”: The Wayward Science of Nutrition in Human Health

  2018cites this paper
• Développement d'un algorithme permettant la prédiction des métastases à partir de mutations germinales et celles du clone fondateur chez des patients atteints du cancer

  2018cites this paper
• CLONAL EVOLUTION AND HETEROGENEITY OF CANCER IN THE CONTEXT OF INDIVIDUALIZED MEDICINE

  2018cites this paper
• Engineering and Study of Biocompatible Nanoceramics

  2018cites this paper
• From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)

  2018influential citation
• Near-Infrared Activated Release of Doxorubicin from Plasmon Resonant Liposomes

  2018cites this paper
• Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals.

  2018cites this paper
• Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few.

  2018cites this paper
• The growing role of precision and personalized medicine for cancer treatment

  2018cites this paper
• Journal of Nanomaterials & Molecular Nanotechnology Nanoparticle Augmented Radiotherapy Using Titanium Oxide Nanoparticles

  2018cites this paper
• Metabolic Dependencies in Pancreatic Cancer

  2018cites this paper
• Evidence-Based Strategy for Cancer Prevention: Advocating for the Adoption of Black Cumin (Nigella sativa) Herbal Gardens in Zimbabwe

  2018cites this paper
• Conventional Treatment of Cancer Realities and Problems

  2018cites this paper
• UK newspaper reporting of the NHS cancer drugs fund, 2010 to 2015: a retrospective media analysis

  2018cites this paper
• Nanoparticle Augmented Radiotherapy using Titanium Oxide Nanoparticles

  2018cites this paper
• Acridone suppresses the proliferation of human breast cancer cells in vitro via ATP-binding cassette subfamily G member 2.

  2017cites this paper
• Regional anesthesia and analgesia in cancer care: is it time to break the bad news?

  2017cites this paper
• Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime

  2017cites this paper
• Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years

  2017cites this paper
• Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.

  2017cites this paper
• Do new anticancer drugs really work? A serious concern

  2017cites this paper
• Targeting Membrane Lipid a Potential Cancer Cure?

  2017cites this paper
• Factors influencing hematologists-oncologists’ prescription of chemotherapy drugs in cancer treatment in Iran: aninterview-questionnaire study

  2017cites this paper
• Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

  2017cites this paper
• Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?

  2017cites this paper
• Vitamin C Against Cancer

  2017cites this paper